Angiotensin II is an eight-amino-acid octapeptide hormone (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) produced by ACE-mediated cleavage of angiotensin I. It is the primary effector molecule of the renin-angiotensin-aldosterone system (RAAS), acting predominantly through AT1 receptors to regulate blood pressure, fluid balance, inflammation, and metabolic function. Chronic elevation transforms RAAS from an acute adaptive system into a driver of chronic inflammatory disease.
Think of angiotensin II as the fire marshal who never stands down. In a normal building emergency, the fire marshal arrives, raises the alarm, seals the doors, turns on sprinklers (vasoconstriction, water retention), and evacuates people to safety. Once the fire is out, they leave. But imagine the fire marshal stays permanently, keeping all doors locked, sprinklers running, and alarms blaring 24/7. Now the building can't function—doors won't open for deliveries (insulin resistance), water floods the basement (edema), and the constant alarm stress damages the walls themselves (endothelial dysfunction, fibrosis). The alarm system even starts calling in reinforcement alarms from other buildings (NF-κB activation recruiting immune cells). What was designed as a short-term protective response becomes the source of destruction when it never turns off. That's chronic angiotensin II elevation in modern metabolic disease—a rescue system stuck in the "ON" position, creating the emergency it was meant to prevent.
Angiotensin II is formed when ACE (angiotensin-converting enzyme 1) on pulmonary and renal vascular endothelium cleaves two amino acids from the C-terminus of angiotensin I, converting the inactive decapeptide (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu) into the active octapeptide. The specific cleavage site is His-Leu, yielding Asp-Arg-Val-Tyr-Ile-His-Pro-Phe.
Once formed, angiotensin II exerts its effects through two primary G-protein coupled receptors:
AT1 receptor pathway (pathological when chronically activated):
- AT1 receptor (Gq-coupled) → phospholipase C activation → IP3 + DAG production
- IP3 → intracellular Ca²⁺ release from sarcoplasmic reticulum → vasoconstriction via smooth muscle contraction
- DAG → PKC activation → multiple downstream cascades:
- NF-κB nuclear translocation → transcription of IL-6, IL-8, TNF-α, ICAM-1, VCAM-1, MCP-1
- NADPH oxidase activation → superoxide (O2•−) production → Reactive Oxygen Species generation → oxidative damage
- IRS-1 serine phosphorylation (Ser307) → insulin resistance (blocks insulin receptor signaling)
- AT1 → JAK2/STAT3 pathway → pro-inflammatory gene transcription
- AT1 → ERK1/2 and p38 MAPK activation → cell proliferation, hypertrophy, fibrosis
- Stimulates Aldosterone release from adrenal zona glomerulosa → sodium/water retention via epithelial sodium channels (ENaC) in distal tubule and collecting duct
- Triggers vasopressin (ADH) secretion from posterior pituitary → aquaporin-2 insertion → water reabsorption
- Activates sympathetic nervous system via central effects (circumventricular organs lack blood-brain barrier) → noradrenaline release
- Stimulates thirst centers in hypothalamus (subfornical organ, OVLT)
- Direct renal effects: efferent arteriole vasoconstriction > afferent → maintains GFR during hypotension, but chronically drives glomerular damage
- Stimulates proximal tubule Na⁺/H⁺ exchanger (NHE3) → sodium reabsorption
AT2 receptor pathway (generally protective, but less abundant):
- AT2 receptor (coupled to phosphatases) → bradykinin release, NO production, vasodilation
- Opposes AT1 effects but is downregulated in chronic disease states
- More expressed in fetal tissues; decreases with age
Alternative pathway:
- ACE2 can cleave angiotensin II → Ang 1-7 (Asp-Arg-Val-Tyr-Ile-His-Pro)
- Ang 1-7 binds MAS receptor → vasodilation, anti-inflammatory, anti-fibrotic effects
- This is a critical counter-regulatory mechanism; ACE2 activity opposes the pathological effects of chronic angiotensin II
graph TD
A[Angiotensinogen] -->|Renin| B[Angiotensin I]
B -->|ACE| C[Angiotensin II]
C -->|AT1 receptor| D[Vasoconstriction]
C -->|AT1 receptor| E[Aldosterone release]
C -->|AT1 receptor| F["NF-κB activation"]
F --> G["IL-6, TNF-α, IL-8"]
C -->|AT1 receptor| H[NADPH oxidase]
H --> I[Superoxide O2•−]
C -->|AT1 receptor| J[IRS-1 Ser307 phosphorylation]
J --> K[Insulin resistance]
C -->|AT1 receptor| L[Vasopressin release]
C -->|AT1 receptor| M[Sympathetic activation]
C -->|ACE2| N[Angiotensin 1-7]
N -->|MAS receptor| O[Vasodilation, anti-inflammatory]
style F fill:#ff9999
style G fill:#ff9999
style I fill:#ff9999
style K fill:#ff9999
style O fill:#99ff99
Half-life: 1-2 minutes in circulation (rapid enzymatic degradation by aminopeptidases), necessitating continuous production for sustained effects.
Chronic angiotensin II elevation is a unifying mechanism across the metabolic syndrome cluster: hypertension, type 2 diabetes, atherosclerosis, chronic kidney disease, and non-alcoholic fatty liver disease. In cPNI terms, this represents selfish brain and selfish immune system dysregulation—the stress axes (HPA, SNS, RAAS) remain chronically activated to defend perceived threats (chronic stress, obesity, sedentary lifestyle), but the defense itself becomes the pathology.
Key clinical connections:
-
Chronic stress → RAAS activation: Psychological stress activates the HPA axis → cortisol → increased angiotensinogen production in liver and adipose tissue → more substrate for renin. Simultaneously, stress activates SNS → renal sympathetic nerves → renin release from juxtaglomerular cells. This creates a feed-forward loop where stress sustains RAAS activation independent of blood pressure or volume status.
-
Obesity as RAAS amplifier: Adipocytes produce angiotensinogen; visceral adipose tissue acts as an autonomous RAAS factory. In obesity, local adipose angiotensin II drives inflammation (macrophage recruitment), insulin resistance (IRS-1 serine phosphorylation), and lipolysis (creating free fatty acids that further activate inflammation). This explains why weight loss improves blood pressure even before significant weight is lost—reducing adipose RAAS activity.
-
The inflammation-metabolic nexus: The direct NF-κB activation by angiotensin II establishes that RAAS dysregulation is fundamentally an inflammatory disease, not merely hemodynamic. Elevated angiotensin II means elevated IL-6, TNF-α, CRP. This is why ACE inhibitors and ARBs reduce cardiovascular events beyond blood pressure control—they are anti-inflammatory interventions. Patients with elevated CRP (>3 mg/L) and metabolic syndrome should be evaluated for RAAS overactivity even if blood pressure is "normal."
-
Insulin resistance mechanism: The IRS-1 Ser307 phosphorylation by angiotensin II-activated PKC directly blocks insulin signaling. This is independent of obesity-induced inflammation, creating a dual-hit model: obesity drives angiotensin II production, which then blocks the insulin signaling needed to clear glucose, creating hyperglycemia and further inflammation (AGE formation). Clinically, this means interventions that reduce angiotensin II (ACE inhibitors, ARBs, weight loss, stress reduction) improve insulin sensitivity mechanistically, not just statistically.
-
Chronic kidney disease progression: The efferent arteriole vasoconstriction maintains GFR acutely (adaptive in dehydration), but chronically drives glomerular hyperfiltration → podocyte injury → proteinuria → progressive fibrosis. This is accelerated by angiotensin II-driven oxidative stress and TGF-β expression. ACE inhibitors/ARBs are renoprotective because they reduce intraglomerular pressure and fibrotic signaling.
-
Endothelial dysfunction: Angiotensin II-induced superoxide reacts with nitric oxide (NO) → peroxynitrite formation → loss of vasodilatory capacity, platelet activation, and vascular smooth muscle proliferation (atherosclerosis). This explains why RAAS blockade improves endothelial function measured by flow-mediated dilation before blood pressure changes occur.
Intervention implications:
- Pharmacological: ACE inhibitors (block formation), ARBs (block AT1 receptors), mineralocorticoid receptor antagonists (block aldosterone effects). Note: ACE inhibitors increase bradykinin (protective but causes cough in 10-15%); ARBs do not.
- Lifestyle: Chronic stress reduction (reduces HPA-SNS drive), weight loss (reduces adipose angiotensinogen), regular movement (improves insulin sensitivity, reduces inflammation), sodium restriction (reduces volume-driven renin release), adequate sleep (modulates HPA axis).
- Nutraceutical: ACE2 upregulation strategies (vitamin D, resveratrol, omega-3 fatty acids may increase ACE2 expression, shifting balance toward Ang 1-7 pathway).
Exam-relevant: Angiotensin II is the molecular link between chronic stress, obesity, inflammation, and metabolic disease. Any question about metabolic syndrome, hypertension, insulin resistance, or chronic kidney disease can invoke the angiotensin II → NF-κB → inflammation pathway as a mechanistic explanation. Understanding the AT1 vs AT2 and ACE vs ACE2 balance is critical for clinical reasoning.
- Eight-amino-acid sequence: Asp-Arg-Val-Tyr-Ile-His-Pro-Phe
- Formed by ACE cleavage of angiotensin I at His-Leu bond
- Circulating half-life: 1-2 minutes (rapid turnover requires continuous production)
- Primary receptor AT1 (Gq-coupled, pathological when chronic); AT2 protective but less abundant
- Directly activates NF-κB transcription factor → IL-6, TNF-α, IL-8, adhesion molecules
- Activates NADPH oxidase → superoxide production → oxidative stress and peroxynitrite formation
- Causes insulin resistance via IRS-1 Ser307 phosphorylation (blocks insulin receptor signaling)
- Stimulates aldosterone release → sodium/water retention via ENaC channels
- Stimulates vasopressin release → aquaporin-2 insertion → water reabsorption
- Activates sympathetic nervous system centrally (acts on circumventricular organs lacking BBB)
- Adipose tissue produces angiotensinogen; obesity = increased RAAS substrate
- ACE2 converts Ang II → Ang 1-7 (protective MAS receptor pathway)
- Chronic elevation drives atherosclerosis, glomerulosclerosis, cardiac hypertrophy, hepatic fibrosis
- ACE inhibitors prevent formation; ARBs block AT1 receptors (both reduce CV events independent of BP)
- Normal plasma levels: 10-30 pg/mL; elevated in heart failure, CKD, metabolic syndrome
- Renin-angiotensin-aldosterone axis is the primary regulator of long-term blood pressure (SNS is acute)
- ACE — enzyme catalyzing formation from angiotensin I; primary production site is pulmonary endothelium
- angiotensin I — inactive decapeptide precursor cleaved by ACE to form angiotensin II
- ACE2 — converts angiotensin II to protective Ang 1-7; downregulated in chronic disease states
- Ang 1-7 — protective peptide formed by ACE2; acts on MAS receptor to oppose AT1 effects
- MAS receptor — receptor for Ang 1-7; mediates vasodilation, anti-inflammatory, anti-fibrotic effects
- Aldosterone — mineralocorticoid released by angiotensin II; drives sodium/water retention and fibrosis
- renin — enzyme released by juxtaglomerular cells in response to SNS, low BP, low sodium; cleaves angiotensinogen
- angiotensinogen — precursor protein produced by liver and adipose tissue; substrate for RAAS cascade
- NF-κB — transcription factor directly activated by AT1 signaling; drives inflammatory gene expression
- IL-6 — pro-inflammatory cytokine upregulated via NF-κB pathway; links RAAS to systemic inflammation
- TNF-α — pro-inflammatory cytokine induced by angiotensin II-NF-κB signaling
- Reactive Oxygen Species — superoxide and peroxynitrite generated by NADPH oxidase activation
- insulin resistance — induced by IRS-1 serine phosphorylation; mechanistic link between RAAS and type 2 diabetes
- vasopressin — ADH released in response to angiotensin II; synergizes water retention with aldosterone
- sympathetic nervous system — activated by angiotensin II acting on subfornical organ and OVLT
- chronic low-grade inflammation — sustained by NF-κB-driven cytokine production; hallmark of metabolic syndrome
- atherosclerosis — accelerated by angiotensin II-driven oxidative stress, endothelial dysfunction, and inflammation
- Chronic Kidney Disease — driven by glomerular hyperfiltration, oxidative stress, and TGF-β-mediated fibrosis
- Type 2 Diabetes — linked via insulin resistance mechanism and chronic inflammation
- obesity — adipose tissue produces angiotensinogen; visceral fat is autonomous RAAS source
- ACE inhibitors — block angiotensin II formation; reduce CV events, improve insulin sensitivity, renoprotective
- Cortisol — increases hepatic angiotensinogen production; HPA axis activation drives RAAS
- Noradrenaline — released by SNS activation; stimulates renin release from kidney
- endothelial dysfunction — caused by NO depletion via peroxynitrite formation; precedes atherosclerosis
- TGF-beta — fibrotic cytokine upregulated by angiotensin II; drives cardiac and renal fibrosis